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INTRODUCTION
Vancomycin is a complex tricyclic glycopeptide antibiotic ob-
tained from the Nocardia species Amycolatopsis orientalis. As it 
has strong bactericidal activity against a broad range of Gram-
positive bacteria,
1 vancomycin has been used for more than 50 
years and is the drug of choice for the treatment of infections 
due to methicillin-resistant Staphylococcus aureus (MRSA), Co-
rynebacterium jeikeium, resistant strains of Streptococcus pneu-
moniae, and pseudomembranous colitis. Vancomycin is also 
an alternative drug for people with allergies to penicillins and/
or cephalosporins.
2,3
With the increase in vancomycin use, numerous adverse drug 
reactions (ADRs) have been reported, including red man syn-
drome (RMS), which is an infusion-related reaction peculiar to 
vancomycin. A pruritic, erythematous rash involving the face, 
neck, and upper torso is another typical ADR. Less frequently, 
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vasculitis, anaphylaxis,
4 ototoxicity, neutropenia, fixed drug 
eruptions, fever, phlebitis, nephrotoxicity,
5 thrombocytopenia,
6 
and, more rarely, Stevens–Johnson or drug rash with eosino-
philia and systemic symptoms (DRESS) syndrome have been 
reported.
7 A recent study conducted at six Korean pharmaco-
vigilance centers (PVCs) reported that antibiotics including 
vancomycin were the most prevalent causes of ADRs, and that 
skin manifestations were the most common symptoms in spon-
taneously reported ADRs.
8 Of the 1,418 cases in the study, 3.1% 
were associated with vancomycin.
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Purpose:  With the increase in vancomycin use, adverse drug reactions (ADRs) associated with vancomycin have been reported increasingly more 
often. However, the characteristics of cutaneous ADRs with and without systemic reactions (SRs) have not been described. This study investigated 
the characteristics of spontaneously reported and assessed ADRs associated with vancomycin by a pharmacovigilance center.  Methods:  ADRs 
(n=121) associated with vancomycin in 96 patients were collected from 2008 to 2009. Records from physician- and nurse-reported suspected cases 
of vancomycin ADRs, ADR type, latent period, and laboratory results were compared between cutaneous ADRs with and without SRs.  Results:  The 
main vancomycin-related ADRs were skin rashes (47.9%), hematologic abnormalities (17.36%), fever (12.4%), and elevated serum creatinine (12.4%). 
Significant differences were observed in latent period (days) and the mean change in eosinophils (%) between cutaneous (9.21±9.71 and 1.4±3.4, 
respectively) and other ADRs (14.03±11.71 and -0.5±3.5, respectively). Twelve cases of cutaneous ADRs with SRs had been initially reported as 
cutaneous ADRs only. Mean changes in the eosinophil count were significantly higher for cutaneous ADRs with SRs compared to those without 
SRs.  Conclusions:  Skin rashes accompanied by peripheral eosinophilia, representing suspected immune-mediated delayed hypersensitivity reac-
tions, are a common vancomycin ADR. For the early and exact detection of ADRs associated with vancomycin administration, close monitoring of 
laboratory tests, including complete blood counts with differential analysis, is recommended.
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While cutaneous ADRs are common, the characteristics that 
distinguish cutaneous ADRs with systemic reactions (SRs) from 
those without SRs have not been reported. The present study 
was designed to investigate and compare the characteristics of 
cutaneous ADRs with and without SRs associated with vanco-
mycin.
MATERIALS AND METHODS
ADRs associated with vancomycin were detected at Ajou Uni-
versity Medical Center between January 2008 and December 
2009. An electronic reporting system linked to the order com-
munication system was used by the physicians and nurses to 
report ADRs. Spontaneously reported cases were reviewed and 
assessed by members of the PVC concerning causalities and 
outcomes. After the ADRs were classified according to World 
Health Organization-Uppsala Monitoring Center (WHO-UMC) 
criteria, unlikely or un-assessable cases were excluded from 
further analysis. The characteristics of the cutaneous ADRs 
were compared with the others in terms of demographic data, 
latent period (i.e., days from the start of vancomycin use to de-
velopment of the ADR), and laboratory abnormalities. The cu-
taneous ADRs were further classified into two groups depend-
ing on whether they were accompanied by a SR. Fever, gastro-
intestinal discomfort, hematologic abnormalities, abnormal liv-
er function, and elevated serum creatinine were classified as 
SRs. The two groups were also compared in terms of their labo-
ratory test results, with an emphasis on a complete blood count 
with differential, and on indicators of liver and kidney function, 
including aspartate transaminase (AST), alanine transaminase 
(ALT), blood urea nitrogen, creatinine (Cr), and the level of van-
comycin in some cases. Eosinophilia was defined as an abso-
lute eosinophil count that increased by more than 500/µL or a 
>10% increase in the total white blood count (WBC) in cases in 
which the baseline level was within the normal range. Serum 
vancomycin concentrations were determined by a fluorescence 
polarization immunoassay using a Cobas Integra 800 appara-
tus (Roche Diagnostics, Mannheim, Germany). Pharmacoki-
netic parameters were obtained by the Bayesian method using 
CAPCIL (Simkin, Gainsville, FL, USA).
The data were analyzed using SPSS version 12.0 (SPSS Inc., 
Chicago, IL, USA). All descriptive statistics are presented as the 
frequency and mean±standard deviation. Statistical signifi-
cance was evaluated using a t-test. A P-value <0.05 was regard-
ed as statistically significant.
RESULTS
A total of 121 ADRs associated with vancomycin was reported 
in 96 patients during the study period (Table 1). Overall, the 
mean age of the patients (57 men and 39 women) was 48.5±
17.8 years (range 12-90 years). The clinical department report-
ing ADRs most frequently was neurosurgery (18 cases), followed 
by orthopedics (17 cases), pulmonology (11 cases), and hema-
to-oncology (10 cases). Most cases were probable/likely (37 
cases, 38.5%) and possible (53 cases, 55.2%) based on WHO-
UMC criteria. More than 80% of the vancomycin-associated 
ADRs were reported by physicians. The mean latent period was 
11.1 days.
The main vancomycin-related ADRs were skin rashes (58 cas-
es, 47.9%), hematologic abnormalities (21 cases, 17.4%), fever 
(15 cases, 12.4%), elevated serum Cr (15 cases, 12.4%), and liver 
function test abnormalities (7 cases, 5.8%). Nausea (2 cases, 
1.7%) and hearing difficulties (2 cases, 1.7%) were reported rare-
ly (Figure). The mean latent period for cutaneous ADRs was 9.2 
Table 1. Characteristics of spontaneous ADRs associated with vancomycin
Characteristics Frequency
Sex (M:F) 57 (59.4%):39 (40.6%)
Age (yr) 48.5±17.8
Clinics
Neurosurgery 18
Orthopedics 17
Pulmonology 11
Hemato-oncology 10
Neurology 8
Plastic surgery 6
Others 26
WHO-UMC criteria
Definite 2 (2.1%)
Probable 37 (38.5%)
Possible 53 (55.2%)
Unlikely 4 (4.2%)
Latent period (days) 11.1±10.8
Reporters
Physician 80 (83.3%)
Nurse 16 (16.7%)
ADR, adverse drug reaction; WHO-UMC, World Health Organization-Uppsala 
Monitoring Center.
Figure. Classification of 121 spontaneous ADRs associated with vancomycin 
administration.
Skin rash
Homatologic abnormalities
Fever
Elevated serum creatinine
Elevated liver enzyme
Nausea, vomiting
Hearing difficulty
Tingling sense
47.9%
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1.7% 0.8%An et al.
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days, which is significantly shorter than the 14-day mean latent 
period for the other ADRs (P=0.032, Table 2). Other than that, 
the mean change in eosinophils (%) was significantly different 
between the cutaneous and other ADRs (P=0.033, Table 2). 
Furthermore, 29% of the cutaneous ADR cases were reported 
as ADRs detected only on the day of vancomycin administra-
tion. While one case (2.6%) of nausea and vomiting was report-
ed immediately after vancomycin administration, the rest of 
the ADRs were identified several days after vancomycin use. No 
significant difference was detected in the mean age, sex, or 
therapeutic drug monitoring level between the patients with a 
cutaneous ADR and those in the other ADR group (Table 2).
Among the 58 cutaneous ADR cases, 9 were reported as man-
ifesting a SR such as leukopenia, thrombocytopenia, and ele-
vated liver enzymes or Cr; the remaining 49 cases manifested 
only cutaneous ADRs. Notably, a difference in the number of 
cutaneous ADRs with systemic reactions was observed between 
the spontaneously reported results and reviewed results. Twelve 
cases of cutaneous ADRs with SRs were reported as skin rashes. 
Ten cases of eosinophilia, 8 of elevated liver enzymes, 4 of cyto-
penia, and 2 of elevated creatinine were missed during sponta-
neous reporting. Therefore, we ultimately compared 37 cases of 
cutaneous ADRs without SRs and 21 cases with SRs according 
to the demographic data, latent period, and laboratory test re-
sults, including the peak and trough therapeutic drug monitor-
ing levels, complete blood count with differential, AST, ALT, and 
Cr. No significant differences were observed in age and sex dis-
tribution between the two patient groups. The baseline com-
plete blood count with differential and liver enzyme and Cr val-
ues showed no significant differences. Furthermore, regarding 
the mean change in laboratory values, only the percentage of 
eosinophils was significantly higher in patients who had cuta-
neous ADRs with SRs compared to those without SRs (3.6±4.6 
vs. 0.2±1.7%, respectively; P=0.018, Table 3).
DISCUSSION
Antibiotic ADRs are not a rare occurrence among hospitalized 
patients, irrespective of their age. In prospective trials, treat-
ment-related adverse reactions were observed in 22-43% of pa-
tients in vancomycin arms.
9,10 The clinical manifestations of an 
antibiotic allergy may be cutaneous, organ-specific (e.g., hema-
tologic abnormalities, hepatitis, and nephritis), or systemic 
(e.g., anaphylaxis, fever, or a combination).
11 Among them, skin 
rashes comprised about 5% of the ADRs.
The present study focused on cutaneous ADRs induced by 
vancomycin among spontaneously reported ADRs at a univer-
sity hospital. In particular, to discriminate cutaneous ADRs 
with and without SRs, PVC teams evaluated both the reported 
data from medical personnel and changes in the patients’ labo-
ratory results, including their blood counts, liver and renal 
function tests, and therapeutic vancomycin monitoring levels 
before and after the ADR. Of 58 cutaneous ADR cases (36.2%), 
21 simultaneously experienced SRs. Among them, 10 cases had 
newly developed eosinophilia with or without other manifesta-
tions after the administration of vancomycin. The mean change 
in eosinophil count was significantly higher in cutaneous ADRs 
with SRs compared to those without SRs. This suggests that at 
least 17% (10 cases) of the spontaneously reported cutaneous 
ADRs (58 cases) due to vancomycin were immune-mediated, 
delayed hypersensitivity reactions.
Table 2. Comparison of clinical characteristics between cutaneous and other 
ADRs
Characteristics Cutaneous 
ADRs (n=58)
Other ADRs 
(n=38)
P-value
Sex (male) 34 (58.6%) 23 (50.6%) 0.854
Age (yr) 47.2±17.7 50.6±18.0 0.369
Latent period (days) 9.2±9.7 14.0±11.7 0.032
Latent period <1 day 17 (29.3%) 1 (2.6%) 0.001
Mean of peak TDM (mg/L) 31.4±12.9 33.9±12.5 0.492
Mean of trough TDM (mg/L) 11.6±6.9 13.04±9.1 0.513
Mean change in eosinophils (%) 1.4±3.4 -0.5±3.5 0.033
ADR, adverse drug reaction; TDM, therapeutic drug monitoring.
Table 3. Comparison of cutaneous ADRs with and without SRs
Characteristics
Cutaneous ADRs 
without SR (n=37)
Cutaneous ADRs 
with SR (n=21) P-value
Sex (M) 22 (59.5%) 12 (57.1%) 0.863
Age (yr) 46.1±17.5 49.2±18.3 0.528
Latent period (days) 8.1±8.4 11.2±11.6 0.259
Peak TDM (mg/L) 31.33±14.48 33.27±11.11 0.976
Trough TDM (mg/L) 10.22±6.08 13.54±7.93 0.230
Baseline laboratory values
WBCs 11,944±23,723 8,445±4,512 0.518
Neutrophils (%) 64.9±21.5 68.2±12.1 0.559
Eosinophils (%) 2.5±2.3 3.1±4.2 0.098
Platelets 273.2K±140.9K 238.9K±103.7K 0.514
AST (U/L) 34±52.5 33.9±25.9 0.995
ALT (U/L) 33.7±47 43.6±44.7 0.471
Cr (mg/dL) 0.8±0.4 1.4±1.8 0.218
Mean change in laboratory values
WBCs -4,957.1±27,215.5 223.5±3,089.8 0.44
Neutrophils (%) -1±9 -4.7±13.3 0.359
Eosinophils (%) 0.2±1.7 3.6±4.6 0.018
Platelets -17.2K±101.4K -2.5K±84.6K 0.616
AST -2.7±14.5 -0.4±22.6 0.747
ALT 1.5±17.3 -3.9±19.3 0.526
Cr 2.35±0.12 1±0.18 0.182
ADR, adverse drug reaction; SR, systemic reactions; WBC, whole blood count; 
K, 1,000; AST, aspartate aminotransferase; ALT, alanine aminotransferase; Cr, 
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To date, the most common vancomycin-related ADR is a cu-
taneous adverse reaction (i.e., RMS). RMS has been reported in 
3.7-50% of infected patients and up to 90% of healthy volun-
teers.
12-14 It is thought to be the result of non-immunologic mast 
cell degranulation
15 and histamine release following a rapid in-
fusion of vancomycin. Therefore, RMS can be prevented by de-
creasing the rate or dose of infused vancomycin and by pre-
medication with antihistamines. Vancomycin-induced ana-
phylaxis, an IgE-mediated immediate hypersensitivity reaction, 
is rare but does occur, and the readministration of vancomycin 
may cause bronchospasm or collapse in affected patients.
4 De-
layed hypersensitivity reactions caused by vancomycin can be 
manifested as DRESS syndrome, which is characterized by a 
skin rash, fever, eosinophilia, and visceral involvement (e.g., in-
terstitial nephritis and hepatitis).
7,16-19 In our study, two patients 
showed a skin rash, fever, and eosinophilia, but no visceral in-
volvement occurred in either case. In another patient diag-
nosed initially with DRESS syndrome, eosinophilia was aggra-
vated during vancomycin use. In a previous study, vancomycin 
skin tests could not predict the severity of RMS
20; however, more 
recently developed skin tests, including intradermal and patch 
tests, may be useful in predicting glycopeptide-induced cuta-
neous adverse reactions.
7,21
While 29.3% of the 58 patients with a cutaneous ADR were 
found to have rashes on the day of vancomycin use in this study, 
the mean latent period was longer than a week in both the cu-
taneous and other ADR groups. Although the results of a sec-
ondary challenge with vancomycin were unknown in most cas-
es, in general, cutaneous ADRs occurring several days or weeks 
after exposure to the suspected medications are suggestive of 
immune-mediated hypersensitivity reactions. The present study 
indicates that increased suspicion of systemic manifestations 
and a more thorough investigation of laboratory results in cases 
of cutaneous ADRs may help detect cutaneous ADRs with SRs 
earlier and reduce unnecessary hospitalization caused by ADRs.
ADRs related to vancomycin may be synergistic with other 
drugs. Both vancomycin and narcotics induce dose- or rate-de-
pendent mast cell degranulation
22 and likely synergize to pro-
duce adverse reactions.
1 Muscle relaxants
23 and radiocontrast 
media may induce mast cell degranulation; thus, synergism may 
be observed when they are used simultaneously with vanco-
mycin. Most of these cases were reported from the departments 
of orthopedics and neurosurgery, where the use of narcotics, 
muscle relaxants, and radiocontrast media is more prevalent 
compared to other departments. However, the concomitant 
use of narcotics or muscle relaxants in cutaneous ADRs with 
SRs did not exceed that in patients with cutaneous ADRs with-
out SRs.
To investigate whether the serum vancomycin concentration 
could influence the development of ADRs, the results of thera-
peutic vancomycin monitoring were reviewed in 51 patients. 
Vancomycin has been shown to degranulate cutaneous mast 
cells and cause a dose-dependent area of flare in suspected pa-
tients and healthy volunteers.
20 However, in the current patient 
comparison, no difference was detected in the peak and trough 
levels of vancomycin therapeutic dose monitoring in a compar-
ison of cutaneous and other ADRs, and between cutaneous 
ADRs with and without SRs.
This study based on spontaneously reported ADRs in a uni-
versity hospital has certain limitations. The prevalence of van-
comycin-induced cutaneous ADRs was not estimated and the 
documentation of skin rashes varied. However, we identified 12 
more cases of cutaneous ADRs with SRs among the 58 reported 
cases of skin rashes, and one-third of the patients with a vanco-
mycin-related cutaneous ADR may have had more severe reac-
tions (e.g., internal organ involvement).
With the increasing use of vancomycin due to the emergence 
of MRSA and resistant coagulase-negative staphylococci, a high 
index of suspicion and rapid, exact diagnosis are necessary. We 
suggest that close monitoring of a patient’s laboratory values, 
including a complete blood count with eosinophils, may facili-
tate the detection of cutaneous ADRs with SRs. In addition, 
health care professionals should be cautious of SRs and skin 
rashes during vancomycin treatment.
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